Charlty reglstration number.. 1210455 LMS -RESEARCH LEIOMYOSARCOMA RESEAKH UK TRUSTEES. REPORT AN UNAUDrrED FINANCIAL STATEMENTS FOR THE pERD 14 OCTOBER 2024 TO 31 OCTOBER 2025 Godfrey Laws & Co Ltd
Lelomyosarcoma Research UK Contents Pag• Reference and Admlnistrative Oetails Trustees. Report Irsdependent Examlner's Report ststernent of Financial Actlvities statement of Flnancial Posltion Ntstes to the Flnanclal sratements The followlng pages do not forrn part of the 5totutory accounts: Detslle# Statement of Flnanclal Activltles io
Leiomyosarcoma Research UK Reference and Admlnlstrative Detalls For the Perlod 14 October 2024 to 31 October 2025 Trust••• Mr Colln Grandison (appointed 14/LOI20241 Ms Maisie England Chair lappolnted 14110120241 Ms Julia Casimo lappointed 14110120241 Charlty Numb•r 1210455 Prlnclpil Addr•• 167 - 169 Great Portland Street London WIW SPF Ind•pnd•nt Ex•mln•r Howard Ashmore FCA Godfrey Laws & Co Ltd Chartered Accountsnts 65 Knowl Plece Wllbury Way Hitchln Hertlordshire SG4 OTY Page I
Leiomyosarcoma Research UK Trustees. Report For the Period 14 October 2024 to 31 October 2025 The trustees present their report and the financial statements for the perlod ended 31 October 202S. ObJ•ctlv•¥ and Actl¥ltl•¥ Alm8 and ObJ•ctlv•• rhe relief of sicknes5 and preservation of health for people sufferlng from Leiomyosarcoma la type of rore cancer that grows In Smooth muscles) In the United Klngdom. in parricular but not exclusively bv., lal Educating the putillc. those suffering from Leiomyosarcoma. and others about Leiomy05arcorna and raising aV4areness of Its prevalence, diagn0515, treatment and latest research. Ibl Promoting and supporting research into Leiomyosarcoma and disseminating the useful results for the publlc benefit. Icl Providin9 support forums, Informatlon. practlcal advlce an¢ Support for people affected by Leiorny05areoma, their famllies and frlends. Sl9nllle•rbt Actl¥ltl•¥ The main activities of the charity within the reportlng period have been the establlshment of the Pathflnder Neh¥ork, whlch will promote research Into Leiomyosarcoma. We have also worked on capaclty and Infrastructure bullding for the charity, estab115hing a website and social media connectyons. Publlc B•n•fSt The Trustees have had regard to the guldance Issued by the C harlty Commlsslon on publlc beneflt. Athl•¥•m•nt• •nd P•rform•nc• M•ln A<hl•v•m•nts The LMS Pathllnder Nerwork, wa$ esrabllshed and met several tlmes In the perlod. It brlngs tO9ether healthcare professlonals frorn acr05S the UK with an Interest In sarcoma. Members Include cllniclans. biologlcal researchers, nurse practitioners, data scientlsts, and other specialists. The aim of the neiwork Is to promote the sharing of best practlce, foster closer collaboration, ané support the development of novel and dlsruptive research and Innovatlons to improve outcomes for patients with sarcoma. C urrently, the network Includes representatlon from all UK Soft T15sue Sarcoma Centre5 of Excellence. We developed our cornmunlcatlons capaclty with patients and have recently updated our website In order to Inlorm and engage and support people whose Ilves have been affected by Lelomyosarcoma. Fln•ncl•l R•vl•w Fln•nclal Po•ltlon The charlty recelved Income ol E43,036 In the year and had expenses of É2,133, leavlng a surplus lor the perlod of E40,903 our Income tame only from publlc fundra151ng and the Tru5tee5 would like to expre$5 thelr slncere thanks to all donor5 and fundra15ers. Given that thls was the charity's flrst period of operatlon. the Trustees are pleased wlth the flnancial position at the end of the perlod. R•••r¥•• Pollcv Unrestricted reserves at the 31 October 2025 were £40,903. This allows the Trustees, whlle eontinuing to fundra15e, to fSnancially support relevant projects. A5 a new charity with mlnimal runnln9 Costs, we intend Inltially to ensure we hold free reserves of a minimum of £s.000. Our reserves at the 31 October 2025 were well in excess of this figure. but we anticipate that In the subsequent flnanclal period we will de51gnate or expend fund5 toward5 supported projects. Golng C•n¢¢rn ThÈrÈ are no uncertainties In relatron to the charlty's continuarion as a going concern. Page 2
Leiomyo$ar¢oma Re$earth UK Trustees. Report (contlnued) For the Period 14 October 2024 to 31 October 2025 Statfft•nt (trf Try•t•••' R••ponlbllltl•• The trustees are respon51bie for preporlno the Trustees, Report anl the financlbl srjtements In accoreonce With 8ppIIcable law and Vniteo Kin9dorn AccountiThq Standards (United Klngoorn Generally Accepted Accountyng Pracbcel. The appllcablt ro charitles li Eryqljno and Wales reGuires the trustees to prepare nancial ststernents for eatr financial year ¥Yhlch give a true ralr view ol Ihe Slale of affairs of the charity and of the Intominq re5ource5 én applicatyèn ol resgurce$ of the cha.ity for that period. In preparing the financial $taternents the trustee$ are reouire £eit¢r suif•tyl a¢¢ounOfi9 politles and thth apply thern ¢on%lste•Uv obs¢rye the rne¢h&ds and principle% Ill the Charily SORP.. rnake lud4mbyfbts •nd •c¢ountin9 e$timare8 fhat are re•son•¥i¢ •fid prudent,. ond prepare the financiol stotements on the going knoncevn bo515 tsnless It i¥ Inappropriate to presume that the charity lll conrlnue In buslnes5. The irustees are respon51ble for keeping adequate accoup.tln4 records whlch dlsclose with reasonable accuracy ai anytime thE finèncial yosltion of the charlty and to enable them to en$ure Lhat the accounrs ¢¢mp'y with the C harlts¢J Act 2011, the cbariti¢s Ilccounts Ind Reportjl Rtsulatiori 2006 and the prov1510ns of the trust deed. They are also respon51ble for safegubrdlng the assets of the charlTr and hence or taklng reosonable steps f¢r tre pieventlon and detecdon 01 frjud and orh¢r Irregularltle$. The rru%t¢ei are responslble foT tre malp.tenance and Integflty of the rorporate ané flr4an¢lJl Informatlon Included on Ine Charity's Wtbslte Lejislayon In the tyniteo K Ingdorys o¢¥érnln£ Ihe prt)a"a¥ion and 015¥emir,?t.on of finaTrclJl •t•t¢menrs m•y dlllvr from i¢glslatyon In other iurisdictlons. The tru$tee¥' r•porr w•1 4pproved bv the board of trusrèe5 •nd 51gned on Its behjff by-. MS Maisle Engl4rn Truitee Date i o/&/za2è Page 3
Lelomyosartoma P£search UK Independent Examiner's Report to the Trustees of Lelomyosarcoma Research UK For the Perlod 14 October 2024 to 31 October 2025 I report to the trustees on my examlnation of the accounts of LeioFnyosarcoma Research UK (the Trust) for the period ended 31 October 2025. R••ponslbllltl•• •nd B•*ls of R•port As the charity trustees of the Trust you are responsible for the preparatlon of the JCCOLtnts In accordance with the requlrements of the C harities Act 2011 1.the Act~l. I report in respect of my examination of the Trust's aceounts carried out undei sectlon 145 of the 2011 Act and In carrylng out my exornination, I have followed the applicable Direction5 glven by the C harlty Commlsslon under section 14515llbl of the Act. Ind•p•nd•nt Ex•mln•r'¥ St•t•m•nt I have completed my exarnination. I conflrm that no material matters have come to my attentlon in connectlon with the examlnation giving me cause to belleve that In any tnaterial respect.. l. accountlng record5 were not kept In respect of the Trust as reoulred by sectlon 130 of the Act,. or 2. the accounts do not accord with those record5,' or 3. the accounrs do not comply ¥Yifh the applicable requirements concernlng the form and content5 of atcounts set out In the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'rru¢ and falr vlew, whi£h Is not a matter considered as part of an Independent examination. I have no concerns and have come acro55 no other matter5 In connection v41th the examlnatlon to ¥Yhlch attention should be d In thls report In order to enable a proper understandlng of the accounts to be reèched. Howard Ashmore FCA Date l?- 08-20J• 65 Knowl Piece Wilbury Way Hitchin Herttord$hire SG4 OTY Page 4
Lelomyosarcoma P£search UK Statement of Flnanclal Actlvltles For the Perlod 14 October 2024 to 31 October 2025 31 October 2025 Vnr¢strl¢t•d fund• Not•• INCOME AND Et4DOWMENTS FROM: Donatlons and legacies 43,036 expeNOITURe ON: Ralsing funds 12, 1331 NET INCOME 40,903 NET MOVEMENT IN FUNDS RECONCILIATION OF FUNOS: 40,903 Ttstal funds brought forward TOTAL FUNDS CARIUED FORWARD 40,903 The notes on pages 7 to 9 form part of these flnanclal statements. Page S
ststement ot Flnancial Posltl AS At 31 October 2025 JI Octob•r 1025 ilnY••trl¢t• fundb CUIUIEirf ASMTS Ca$h at bank In h•nd 41,503 41,503 Cr•dltor•: A¥h•uTht• Vlllng (+ Wlthln On• Y••r 16001 IIET CUIUIEiif ASHT• {U1LITIES> 40,903 TOTAL ASItT LEM CURRE UAVLUTiQ% 40.903 NeT ASSE 40.903 FigNDS OF THE CIIAAXYY Unrestrttd Funds 40,9QJ TOTAL VUII 40,903 rin b•haW ol board r Colln Grnndo Trustv D•t• The 0t5 7 10 9 form of these nnan(1•15tstem•nts.
LeioMyosaom3 Research UK hk>tes to the Financial Statement$ For the Period 14 October 2024 to 31 October 2025 l. General Inforrnatlon Leiomyosarcoma Research UK Is a Charitable Incorporated or9anisatlon registered with the Charity Commission, reglstered charity number A2L0455. The prlncipal addre55 15 167 - 169 Great Portland Street, London, WIW SPF. 2. Acc?untln9 Pollrl•¥ 2.1. Bas1• of Pr•paratlon of Flnanclal Statements The financial staternents have been prepared In accordance wlth the C haritles SORP IFRS 1021 'Accounting and Reporting by C harities,. Statement of Recommended Practice applicable ro charities preparin9 thelr accounts in accordance with the Flnancial Reporting Standard applicable In the UK and Republic of Ireland IFRS 1021 (effective l January 20191. Financial Reporting Standard 102 'The Flnancial Reporting Standard appllcable in the UK and Republic ol Ireland. and the C hariiies Act 2011. The charity Is è Publlc 8eneflt Enrity as deflned by FRS 102. 2.2. Incomlng R•iourc•s All Incomlng resources are Included In the $tatement of flnancial actl¥ltles when thé charlty Is entlded to, and vlrtually certain to recelve, the incorne and the amount can be quantlfled wlth reasonable accurècy. The rollovling policies are applied to particular categorles of Income.. Voluntary Income Is recelved by vlay of grants, donatlon5 and glft5 and ss Included In full in the Statement of Flnancial Actlvities vlhen receivable. Grants, where entitlement Is not conditional or* the dellvery of a speclflc performance by the charlty, are recognised when the charlty becomes uncondltionally entiUed to the grant. Donated servlces and fatllitles are Included at the value to the charity where this can be quantifled. The value of servlces provided by volunteers has not been Included In theseaccounts. Investment Income Is Includetl when recelvable. Incoming resources from 9rants, where related to performance and speciflc dellverables,ore accounted ror a5 the charity earn5 the right io consideration by its performance. 2.3. R••ourc•• Exp•nd•d Llabllltle5 are reco9nlsed as expendlture as soon as there is a le9al or con5tructlve obllgation commltting the charlty to that expendlture. it Is probable that a transfer of economlc beneflts wlll be requlred In settlement and the amount ol the obllgation can be measured reliably. Expenditure Is accounted for on an accruals basls and has been classilled under headlngs that aggregate all c05t related to the category. Where costs cannot be dlrectly attributed to partlcular headlngs they have been allocated to actlvltles on a basls conslstent with the use of resources. 2.4. Cash •nd Cash Equl¥al•nt• Cash and cash equivalents are basic flnanclal assets and Include cash In hand and deposlts held èt call wlth banks, other short-term highly Ilquld Investynents thar mature In no more than three months from the date of acquisition and are readily convertible to a known amount of casli wlth insignificant risk of change In value, and bank overdrafts. 3. Incom• from Donatlonl and L•gacl•% 31 Octob•r 2025 Unr••trlct•d rund• Donatlons and glfts 43,036 Page 7
Leiomyosarcoma Research UK rtes to the Financial Statements {continued) For the Period 14 October 2024 to 31 October 2025 An•lysls of Exp•ndltur• 31 Ottob•r 2025 A¢tl¥ltl•¥ und•rtak•n dlrectly Support co•t¥ (see note 51 Total Ralslng funtls 1,259 874 2,133 Support C••t• 31 O¢tob•r 2025 R•l•lng lund• Premises expenses General administrabon 96 778 874 6. Ind•p•nd•nt Ex•mln•r'¥ R•mun•r•tlon 31 Octob•r 2025 lThdependent examlnatlon ol the financlal statements 600 A¥•r•9• 14umb•r Ol Empl•y••• Average number of employees during th p•rlod wa5.. NIL 8. Cr•dltors: Amount• F•lllng Du• Wlthln On• Y••r 31 O¢tob•r 2025 Accruals ond deferred Income 600 Mo¥•m•nt In Fund• A••t14 O¢t•b•r 2024 As•t3A Octob•r 2025 Incorn• exp•ndltur• Vnrstrl¢t¢d lun0• General. General unrestricted Ivnd 43.036 12,1331 40,903 Tot*1 funds 43.036 12, 1331 40,903 Page 8
Leiomyosarcoma Research UK Notes to the Financlal Statements (contlnued) Forthe Period 14 October 2024 to 31 October 2025 10. Tr•n•*ctlons wlth Trust••s None of the trustees received any rernuneration or any other beneflts from an omployment with the <h•rity or a related entity during the current year. Ourlng the year, expenses pald to thlrd parties totaling £207.43 were relmbursed to I trustee. These expenses were Incurred by the trustee actlng as an agent for the charity. 31 Octob•r 1015 other Expenses 207 The expenses related ro Admlnlstration & Marketing.. £207.43 Icomprlslng customlsed brJnde¢ rlbbons, Reglstere Address Fee, Web Hostlng Fee, and Virtual Office Feel. No other trustees were pald any expense5 or received any other beneflts durlng rhe year. I l. R•l•t•d Party Dl•rlosur•• There have been no related party transactlons In the reportlng perlod that requlre dlsclosure, except for those disc105ed In the Transactions with Trustees note. Page 9
Lelomyosarcoma Research UK Detailed Statement of Financial Activities Forthe Period 14 October 2024 to 31 October 2025 31 Octob•r 202$ Total fund• INCOME AND ENDOWMENTS FROM: Donatlons and 1•9acles Donatlons and gifts 43,036 43,036 43,036 EXPENOITURE ON: R•l¥lng fund• Advertlsin9. markering, dlrect mall and publlclty Travel and subsistence expenses Insurance Just Glvlng Subscrlptlon5 Vlrtual office rte 1821 14131 15631 12011 1961 11781 16001 Wetyslte costs Independent examlner's fees 12, 1331 12,1331 NET INCOMe 40,903 Page 10